

Special Issue

Drug Discovery, Development and Delivery: Current Status and Future Perspectives

Message from the Guest Editors

Biomedicines is excited to announce a new Special Issue, entitled "Drug Discovery, Development and Delivery: Current Status and Future Perspectives".

This Special Issue aims to explore the groundbreaking advancements fundamentally reshaping the future of medicine. We seek contributions that highlight the synergistic integration of cutting-edge computational and experimental methodologies to accelerate the discovery, optimization, and characterization of novel therapeutic agents.

A core focus is on how these diverse strategies can be leveraged to effectively overcome critical challenges, particularly addressing resistance mechanisms and the complexities of diseases that impact millions globally. We invite research, as well reviews, on patient-centric therapies for a wide range of conditions, including various cancers, resistant infectious diseases, and neurodegenerative conditions like Alzheimer's, along with cardiovascular diseases. Submissions encompassing both synthetic compounds and promising natural products are highly encouraged.

Guest Editors

Dr. Shafi Ullah Khan

1. Inserm U1086 ANTICIPE (Interdisciplinary Research Unit for Cancer Prevention and Treatment), Normandie University, Université de Caen Normandie, 14076 Caen, France
2. Comprehensive Cancer Center François Baclesse, UNICANCER, 14076 Caen, France

Dr. Thet Thet Htar

School of Pharmacy, Monash University Malaysia, Selangor, Malaysia

Deadline for manuscript submissions

31 March 2026



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/250824

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).